Explore All Access
Check if your research matches the topics covered in Future Oncology?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Future Oncology : Impact Factor & More
eISSN: 1744-8301pISSN: 1479-6694
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Future Oncology Key Metrics
CiteScore 
4.9
Impact Factor
< 5
SNIP
0.82
Topics Covered on Future Oncology
Cancer
Lung cancer
Adjuvant
Curcumin
Chemotherapy
Immunotherapy
Crizotinib
Hepatocellular carcinoma
Overall survival
Genotype
Breast cancer
Dexamethasone
Neuroendocrine tumors
Prostate cancer
Gefitinib
Respiratory system
Standard deviation
Sunlight
Clinical trial
Hepatitis B
Future Oncology Journal Specifications
| Overview | |
| Publisher | FUTURE MEDICINE LTD |
| Language | English |
| Frequency | Fortnightly |
| General Details | |
| Language | English |
| Frequency | Fortnightly |
| Publication Start Year | 2005 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
One subscription packed with expert publication services and AI tools to get you published
Brought to you by 
Journal Selection Service
Benefit from our experts' recommendations of 3-5 best-suited journals, accompanied by a detailed Journal Selection report explaining the choices. Make informed decisions.
Journal Submission Service
Streamline your submission process with meticulous manuscript formatting to meet journal guidelines, crafting a tailored cover letter for the editor, and hassle-free account creation and submission
Bundle of AI tools for your research needs
Journal Finder, Paperpal, R Discovery, MindTheGraph and more
Planning to publish in Future Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Future Oncology
Advances in breast cancer risk modeling: integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment
- 1 Dec 2023
- Future Oncology
Sintilimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel regimen as neoadjuvant therapy for resectable gastric cancer and biomarker exploration.
- 22 Nov 2023
- Future oncology (London, England)
Revolutionizing colorectal cancer treatment: unleashing the potential of miRNAs in targeting cancer stem cells.
- 16 Nov 2023
- Future oncology (London, England)
Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Fut. Oncol. 18(23), 2561-2572 (2022).
- 14 Nov 2023
- Future oncology (London, England)
Phase II multicenter trial: first-line immunochemotherapy with or without radiotherapy in metastatic esophageal squamous cell cancer (SCR-ESCC-01).
- 8 Nov 2023
- Future oncology (London, England)
A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER study.
- 8 Nov 2023
- Future oncology (London, England)
Advances in breast cancer risk modeling: integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment
- 1 Dec 2023
- Future Oncology
Sintilimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel regimen as neoadjuvant therapy for resectable gastric cancer and biomarker exploration.
- 22 Nov 2023
- Future oncology (London, England)
Revolutionizing colorectal cancer treatment: unleashing the potential of miRNAs in targeting cancer stem cells.
- 16 Nov 2023
- Future oncology (London, England)
Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Fut. Oncol. 18(23), 2561-2572 (2022).
- 14 Nov 2023
- Future oncology (London, England)
Phase II multicenter trial: first-line immunochemotherapy with or without radiotherapy in metastatic esophageal squamous cell cancer (SCR-ESCC-01).
- 8 Nov 2023
- Future oncology (London, England)
A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER study.
- 8 Nov 2023
- Future oncology (London, England)
Compare Similar Journals with Future Oncology
Select Journals to Compare with Future Oncology
Total journals - 10
You can select up to 3 Journals at a time
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Annals of Oncology
Publisher: ELSEVIER
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Cancers
Publisher: MDPI
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
BMC Cancer
Publisher: BMC
Cancer Medicine
Publisher: WILEY
European Journal of Cancer
Publisher: ELSEVIER SCI LTD
Oncotarget
Publisher: Impact Journals
Clinical Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
0 Journals Selected to compare with
Future Oncology
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Future Oncology
How long has Future Oncology been actively publishing? 
Future Oncology has been in operation since 2005 till date.
What is the publishing frequency of Future Oncology?
Future Oncology published with a Fortnightly frequency.
How many articles did Future Oncology publish last year?
In 2023, Future Oncology publsihed 88 articles.
What is the eISSN & pISSN for Future Oncology?
For Future Oncology, eISSN is 1744-8301 and pISSN is 1479-6694.
What is Citescore for Future Oncology?
Citescore for Future Oncology is 4.9.
What is SNIP score for Future Oncology?
SNIP score for Future Oncology is 0.82.
Who is the publisher of Future Oncology?
FUTURE MEDICINE LTD is the publisher of Future Oncology.
